• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies
Biomed Pharmacother. 2023 Jul 31;165:115242. doi: 10.1016/j.biopha.2023.115242. Online ahead of print.ABSTRACTBladder cancer (BC) is a common and serious type of cancer that ranks among the top ten most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the aggressive nature of cancer cells, and their resistance to medication, managing this disease has become a growing challenge in clinical care. Long noncoding RNAs (lncRNAs) are a group of RNA transcripts that do not code for proteins and are more than 200 nucleotides in length. They play a significant role in controlling cellular pathways and molecu...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 2, 2023 Category: Drugs & Pharmacology Authors: Amirreza Mehmandar-Oskuie Kasra Jahankhani Arman Rostamlou Sepideh Arabi Zahra Sadat Razavi Amirhossein Mardi Source Type: research

Ultrasound-Mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes
CONCLUSION: UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.PMID:37491853 | DOI:10.2174/1567201820666230724151545
Source: Current Drug Delivery - July 26, 2023 Category: Drugs & Pharmacology Authors: Hong Shu Wenhao Lv Zhi-Jian Ren Hui Li Tiantian Dong Yao Zhang Fang Nie Source Type: research

Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer
Biochem Pharmacol. 2023 Apr 26:115564. doi: 10.1016/j.bcp.2023.115564. Online ahead of print.ABSTRACTCellular protein synthesis is accelerated in human colorectal cancer (CRC), and high expression of protein synthesis regulators in CRC patients is associated with poor prognosis. Thus, inhibition of protein synthesis may be an effective therapeutic strategy for CRC. We previously demonstrated that the quassinoid bruceantinol (BOL) had antitumor activity against CRC. Herein, potent tumor growth suppression (>80%) and STAT3 inhibition was observed in two different mouse models following BOL administration. Loss of body and...
Source: Biochemical Pharmacology - April 28, 2023 Category: Drugs & Pharmacology Authors: Ning Wei James Burnett Desirae L Crocker Yixian Huang Song Li Peter Wipf Edward Chu John C Schmitz Source Type: research

Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT
Eur J Pharm Sci. 2023 Jan 5:106372. doi: 10.1016/j.ejps.2023.106372. Online ahead of print.ABSTRACTEpidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKIs) was one of the main drugs in the treatment of non-small cell lung cancer (NSCLC). Previous studies had demonstrated that PDZ and LIM Domain 5 (PDLIM5) played an important role in EGFR TKIs resistance. However, there was no feasible method to eliminate EGFR TKIs resistance by suppressing this gene. Here, we formulated a novel mesoporous silica-loaded PDLIM5 siRNA (Small interfering RNA) nanoplatforms. The results have shown that PDLIM5 siRNA could be effect...
Source: European Journal of Pharmaceutical Sciences - January 9, 2023 Category: Drugs & Pharmacology Authors: Hao Wu Wen-Hao Lv Yang-Yang Zhu Ying-Ying Jia Fang Nie Source Type: research

Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells
Discussion: We conclude that apigenin has a unique fit into the Topo1-DNA functional complex that leads to direct inhibition of Topo1 activity, and suggest that this is the basis for the exceptional interaction with the CRC drug irinotecan. A combined action of these two agents may therefore exert a role to limit local signals that facilitate tumour progression.
Source: Frontiers in Pharmacology - December 22, 2022 Category: Drugs & Pharmacology Source Type: research

The effect of neuropilin-1 silencing on the transforming growth factor- β1-mediated epithelial-mesenchymal transition of colon cancer SW480 cells and its effect on the proliferation and migration of colon cancer cells
In conclusion: silencing, NRP-1 in colon cancer SW480 cells can partially reverse TGF-β1-mediated EMT, reduce the proliferation activity of colon cancer cells, and slow their migration ability. Therefore, NRP-1 may become a new target for the treatment of colon cancer.PMID:36193963 | DOI:10.26402/jpp.2022.2.07
Source: Journal of Physiology and Pharmacology - October 4, 2022 Category: Drugs & Pharmacology Authors: B Zhu Q-Q Zhan Q-Y Liu X Yang Y-H Ge G-Y Ding S Guo W-G Xu Source Type: research

Pages: 1  2  3  4  5  6  7  8  9